check_circleStudy Completed

Contraception, Ovulation Inhibition, Contraceptives, Oral

Study to assess efficacy and safety of Yasmin in an extended cycle regimen

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
184
Trial Dates
May 2002 - January 2004
Phase
Phase 4
Could I Receive a placebo
N/A
Products
Yasmin (EE30/DRSP, BAY86-5131)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

Prospective, multi-center, open, uncontrolled study to investigate the efficacy, safety and acceptance of SH T 470 FA (Yasmin® [30μg ethinylestradiol and 3mg drospirenone]) in an extended cycle regimen of up to 36 weeks for oral contraception in 200 female volunteers
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A